Merck & Co’s Moderna MRNA Stock Holding History

Merck & Co’s Portfolio MRNA Stock Details MRNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$117M	Hold	2,308,190	–	–	33.56%	1
2025 Q4	$68.1M	Hold	2,308,190	–	–	24.64%	2
2025 Q3	$59.6M	Hold	2,308,190	–	–	26.15%	2
2025 Q2	$63.7M	Hold	2,308,190	–	–	29.54%	2
2025 Q1	$65.4M	Hold	2,308,190	–	–	39.83%	1
2024 Q4	$96M	Buy	+2,308,190	New	+$110M	37.19%	1

Other funds holding MRNA

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Merck & Co's MRNA Position: Q1 2026 in Review

Merck & Co held its Moderna (MRNA) position steady in Q1 2026 at 2,308,190 shares worth $117M. The position accounts for 33.56% of the portfolio, ranked #1.

Merck & Co first reported a position in MRNA in Q4 2024 and has held it in 6 quarters since. 723 funds tracked by Wall St. Rank hold MRNA as of Q1 2026.

Merck & Co held 2,308,190 shares of Moderna worth $117M as of Q1 2026.
Merck & Co left its Moderna share count unchanged in Q1 2026.
Moderna made up 33.56% of Merck & Co's portfolio in Q1 2026, its #1 holding.
Merck & Co first reported a position in Moderna in Q4 2024 and has held it in 6 quarters since.
723 funds tracked by Wall St. Rank held Moderna as of Q1 2026.

Based on Merck & Co's 13F filing for Q1 2026, filed 13 May 2026.